Last reviewed · How we verify
CAB Oral Tablets
CAB (cabotegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA.
CAB (cabotegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing the virus from inserting its genetic material into host cell DNA. Used for HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals), HIV-1 infection in treatment-experienced adults with integrase inhibitor resistance (in combination with other antiretrovirals).
At a glance
| Generic name | CAB Oral Tablets |
|---|---|
| Sponsor | ViiV Healthcare |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 2 |
Mechanism of action
Cabotegravir inhibits HIV integrase, an enzyme essential for viral replication. By blocking integrase activity, the drug prevents integration of viral DNA into the host genome, thereby suppressing HIV replication. The oral tablet formulation allows for convenient dosing in treatment-naive and treatment-experienced patients.
Approved indications
- HIV-1 infection in treatment-naive adults (in combination with other antiretrovirals)
- HIV-1 infection in treatment-experienced adults with integrase inhibitor resistance (in combination with other antiretrovirals)
Common side effects
- Diarrhea
- Nausea
- Headache
- Hypersensitivity reaction
- Elevated liver enzymes
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Colchicine in Patients Undergoing Coronary Artery Bypass Grafting After Acute Coronary Syndrome (PHASE2)
- Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (PHASE2)
- Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAB Oral Tablets CI brief — competitive landscape report
- CAB Oral Tablets updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI